GENERIC ONCOLOGY STERILE INJECTABLES MARKET ANALYSIS

Generic Oncology Sterile Injectables Market, by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Jan 2020
Code : CMI562
Pages :151
Formats :
Excel and PDF
Industry : Pharmaceutical

Generic Oncology Sterile Injectables MarketSize and Trends

Generic Oncology Sterile injectabless Market – Insights

Generic oncology sterile injectabless are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectabless have to adhere to regulations by the U.S. Food and Drug Administration (FDA) for the development of these injectabless, which are equivalent to that of branded counterparts. These generic oncology sterile injectabless are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus. These injectabless are available at low prices and therefore, are widely preferred over branded drugs.

Furthermore, R&D for generic drugs require less capital, which increase competition to enter into generic oncology sterile injectabless market as soon as the patent for branded injectabless expire. However, the emergence of biosimilars have increased in the recent past. After Europe, increasing number of biosimilars are approved in the U.S. market. This is expected to drive growth of the generic oncology sterile injectables market growth during the forecast period.

The global generic oncology sterile injectables market size is estimated to be valued at US$ 11,496.7 million in 2019 and is expected to witness a CAGR of 11.5% over the forecast period (2019 – 2027).